Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

Inclusion Criteria: 1. Male or female, 18 years of age or older 2. Elevated LDL-C on current lipid lowering therapy and; prior atherosclerotic cardiovascular disease (ASCVD) event or evidence of ASCVD or without ASCVD but at high risk for ASCVD based on AHA/ACC CVD risk calculator, or aged 40 years and older with diabetes and moderate- to high-intensity statin, or pre-treatment LDL-C 190 mg/dL or greater or heterozygous familial hypercholesterolemia (HeFH) 3. Body mass index (BMI) between 18 and 40 kg/m2 Exclusion Criteria: 1. Females of childbearing potential not using or willing to use an effective form of contraception, or pregnant or breastfeeding, or who have a positive serum pregnancy test at screening 2. Homozygous familial hypercholesterolemia 3. LDL or plasma apheresis within 2 months; lomitapide or mipomersen within 12 months 4. Uncontrolled cardiac arrhythmia, myocardial infarction, unstable angina, PCI, CABG, or stroke within 3 months prior to enrollment 5. Uncontrolled cardiac arrhythmia, myocardial infarction, unstable angina, PCI, CABG, or stroke within 3 months prior to enrollment 6. Newly diagnosed or poorly controlled (HbA1c \>9%) type 2 diabetes 7. Uncontrolled hypertension 8. Moderate to severe renal insufficiency 9. Elevated liver function test at screening 10. Uncontrolled cardiac arrhythmia or prolonged QT on EKG 11. A history of prescription drug abuse, illicit drug use, or alcohol abuse